title: Incidence and treatment of 'no-reflow' after percutaneous coronary intervention.
abstract: BACKGROUND
  Profound reduction in antegrade epicardial coronary flow with concomitant ischemia is seen occasionally during percutaneous coronary intervention despite the absence of evident vessel dissection, obstruction, or distal vessel embolic cutoff. In a prior small series of cases, this "no-reflow" phenomenon appeared to be promptly reversed by the intra-coronary administration of verapamil.
  
  
  RESULTS
  To further understand the prevalence of this syndrome and its responsiveness to the proposed therapy, we reviewed 1919 percutaneous interventions performed between January 1991 and April 1993. During the study period, 39 patients (2.0%) met our criteria for no reflow, 37 of whom were treated with intracoronary nitroglycerin followed by intracoronary verapamil and 2 of whom received intracoronary nitroglycerin alone. An additional 16 patients (0.8%) were given verapamil as part of the management of a flow-limiting dissection or distal embolus (mechanical obstruction). Intracoronary verapamil (50 to 900 micrograms, total dose) improved TIMI flow grade in 89% of no-reflow patients and markedly reduced the number of cineframes between contrast injection and opacification of a selected distal landmark (from 91 +/- 56 to 38 +/- 21 frames, P < .001). By contrast, only 19% of patients with epicardial mechanical obstruction showed improvement in TIMI flow grade after verapamil, with minimal reduction in frames to opacification (from 107 +/- 42 to 101 +/- 69, P = .73).
  
  
  CONCLUSIONS
  The no-reflow phenomenon--reduction in distal flow without apparent dissection or distal embolization--occurs in 2% of coronary interventions. It generally responds promptly to intracoronary verapamil administration, suggesting that distal microvascular spasm may be its etiology.
authors.affiliation: Charles A. Dana Research Institute, Boston, MA.
authors.forename: R N
authors.initials: RN
authors.lastname: Piana
authors.forename: G Y
authors.initials: GY
authors.lastname: Paik
authors.forename: M
authors.initials: M
authors.lastname: Moscucci
authors.forename: D J
authors.initials: DJ
authors.lastname: Cohen
authors.forename: C M
authors.initials: CM
authors.lastname: Gibson
authors.forename: A D
authors.initials: AD
authors.lastname: Kugelmass
authors.forename: J P
authors.initials: JP
authors.lastname: Carrozza
authors.forename: R E
authors.initials: RE
authors.lastname: Kuntz
authors.forename: D S
authors.initials: DS
authors.lastname: Baim
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D003331:Coronary Vessels / Q000601:surgery*; D006801:Humans; D015994:Incidence; D017202:Myocardial Ischemia / Q000453:epidemiology* / Q000209:etiology / Q000628:therapy; D012189:Retrospective Studies; D015607:Stents / Q000009:adverse effects; D014700:Verapamil / Q000627:therapeutic use*
chemical_list: D014700:Verapamil